The impact of COVID-19 on oncology clinical trials is clear. Over 100 trials have been suspended over recent months and the impact to patients, in addition to slowed recruitment, is potentially immense. This interactive dashboard allows you to visualise details of both suspended and resumed clinical trials as a result of COVID-19 and gain insights including:
- At the onset of the pandemic, a high proportion of suspended trials were academic/government sponsored
- As of August 1, approximately 60% of trials initially suspended, have resumed recruiting
Click the image below to filter and identify trial sponsors, drug owners, tumor types, drugs that are impacted, and dive into further detail to view by drug technology, class and target.
These data are a product of CancerLandscape™, a module of CancerMPact®. Kantar will continue to update the COVID-19 Impact on Oncology viewer on a monthly basis. Note that while this underestimates the full impact of COVID-19, as updates to trial registries are voluntary, data from Medidata1 in July suggests a return to normal levels for patients entering oncology trials, compared to a drop of approximately 40% in April.
Contact us to learn more about the CancerLandscape and how it can help you understand the complete drug and trial landscape across US and EU trial registries.
1COVID 19 and Clinical Trials Release 7.0